ALT Altimmune Inc

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

• JMP Life Sciences Conference (New York, NY)Tuesday, May 14, 2024Fireside Chat at 9:00 a.m. Eastern Time

• UBS Obesity Therapeutics Day (Virtual Conference)Thursday, May 23, 2024Fireside Chat at 10:00 a.m. Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Company Contact:Richard Eisenstadt                                                        Chief Financial Officer                                                 Phone: 240-654-1450                                                        ir@altimmune.com

Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com Julia WeilmanBurns McClellanPhone: 646-732-4443jweilman@burnsmc.com

Media Contact:Danielle CanteyInizio Evoke CommsPhone: 619-826-4657Danielle.cantey@inizioevoke.com